These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 26210251)
1. Re: Safety and Efficacy of 70-150 µm and 100-300 µm Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. Tu J; Jia Z; Jiang G J Vasc Interv Radiol; 2015 Aug; 26(8):1251. PubMed ID: 26210251 [No Abstract] [Full Text] [Related]
2. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. Deipolyi AR; Oklu R; Al-Ansari S; Zhu AX; Goyal L; Ganguli S J Vasc Interv Radiol; 2015 Apr; 26(4):516-22. PubMed ID: 25704226 [TBL] [Abstract][Full Text] [Related]
3. Drs. Deipolyi et al respond. Deipolyi AR; Oklu R; Al-Ansari S; Ganguli S J Vasc Interv Radiol; 2015 Aug; 26(8):1251-2. PubMed ID: 26210252 [No Abstract] [Full Text] [Related]
4. Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics. Guiu B; Schmitt A; Reinhardt S; Fohlen A; Pohl T; Wendremaire M; Denys A; Blümmel J; Boulin M J Vasc Interv Radiol; 2015 Feb; 26(2):262-70. PubMed ID: 25311967 [TBL] [Abstract][Full Text] [Related]
5. Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis. Miura JT; Gamblin TC Surg Oncol Clin N Am; 2015 Jan; 24(1):149-66. PubMed ID: 25444473 [TBL] [Abstract][Full Text] [Related]
6. Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads: a prospective study. Shaw CM; Eisenbrey JR; Lyshchik A; O'Kane PL; Merton DA; Machado P; Pino L; Brown DB; Forsberg F J Ultrasound Med; 2015 May; 34(5):859-67. PubMed ID: 25911704 [TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization of hepatocellular carcinoma--agents and drugs: an overview. Part 2. Giunchedi P; Maestri M; Gavini E; Dionigi P; Rassu G Expert Opin Drug Deliv; 2013 Jun; 10(6):799-810. PubMed ID: 23679932 [TBL] [Abstract][Full Text] [Related]
8. Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. Horikawa M; Miyayama S; Irie T; Kaji T; Arai Y AJR Am J Roentgenol; 2015 Oct; 205(4):764-73. PubMed ID: 26397324 [TBL] [Abstract][Full Text] [Related]
9. Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile. Odisio BC; Ashton A; Yan Y; Wei W; Kaseb A; Wallace MJ; Vauthey JN; Gupta S; Tam AL J Vasc Interv Radiol; 2015 Jul; 26(7):965-71. PubMed ID: 25979305 [TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study. Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma. Geschwind JF; Chapiro J Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101 [No Abstract] [Full Text] [Related]
12. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737 [TBL] [Abstract][Full Text] [Related]
13. Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization. Tsochatzis EA; Meyer T; O'Beirne J; Burroughs AK J Hepatol; 2013 Jan; 58(1):194. PubMed ID: 23046673 [No Abstract] [Full Text] [Related]
14. Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma. Chan SL Aliment Pharmacol Ther; 2012 Jul; 36(1):74-5; discussion 75. PubMed ID: 22650492 [No Abstract] [Full Text] [Related]
15. Reply to: "Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization". Park JW; Kim HB; Lee IJ J Hepatol; 2013 Jan; 58(1):195. PubMed ID: 23046675 [No Abstract] [Full Text] [Related]
16. Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma. Sinakos E; Dedes I; Papalavrentios L; Drevelegas A; Akriviadis E Scand J Gastroenterol; 2010 Apr; 45(4):511-2. PubMed ID: 20113152 [No Abstract] [Full Text] [Related]
17. Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future. Woo HY; Heo J Clin Mol Hepatol; 2015 Dec; 21(4):344-8. PubMed ID: 26770921 [TBL] [Abstract][Full Text] [Related]
18. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. Facciorusso A; Mariani L; Sposito C; Spreafico C; Bongini M; Morosi C; Cascella T; Marchianò A; Camerini T; Bhoori S; Brunero F; Barone M; Mazzaferro V J Gastroenterol Hepatol; 2016 Mar; 31(3):645-53. PubMed ID: 26331807 [TBL] [Abstract][Full Text] [Related]
19. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease. Fidelman N; Kerlan RK AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322 [TBL] [Abstract][Full Text] [Related]